Processa Pharmaceuticals Inc (OQ:PCSA)

Business Focus: Pharmaceuticals

Mar 28, 2024 08:15 am ET
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from...
Mar 25, 2024 08:15 am ET
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from...
Feb 21, 2024 08:15 am ET
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from...
Feb 14, 2024 01:00 pm ET
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering...
Feb 06, 2024 08:30 am ET
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering...
Feb 01, 2024 04:22 pm ET
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering...
Jan 26, 2024 09:04 am ET
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering...
Jan 25, 2024 08:30 am ET
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering...
Jan 19, 2024 07:45 am ET
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering...
Jan 18, 2024 07:45 am ET
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from...
Jan 02, 2024 05:06 pm ET
Processa Pharmaceuticals to Present at the Biotech Showcase 2024
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from...
Dec 19, 2023 09:00 am ET
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the safety and efficacy for more cancer patients,...
Dec 14, 2023 08:31 am ET
Thinking about buying stock in Processa Pharmaceuticals, Adobe Inc, Progressive Corp, Hanryu Holdings, or Esperion Therapeutics?
NEW YORK, Dec. 14, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PCSA, ADBE, PGR, HRYU, and ESPR.
Dec 13, 2023 09:00 am ET
Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering...
Nov 30, 2023 08:15 am ET
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from...
Nov 29, 2023 08:15 am ET
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering...
Nov 13, 2023 01:40 pm ET
Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced today with great sadness that Virgil Thompson, Director, passed away unexpectedly on November 9, 2023. Mr. Thompson served on our Board of Directors since we were formed in 2017 and was...
Nov 09, 2023 08:15 am ET
Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from...
Nov 01, 2023 08:15 am ET
Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from...
Oct 20, 2023 09:31 am ET
Thinking about buying stock in Momentus Inc, micromobility.com, Aldeyra Therapeutics, Mullen Automotive, or Processa Pharmaceuticals?
NEW YORK, Oct. 20, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MNTS, MCOM, ALDX, MULN, and PCSA.
Oct 17, 2023 09:31 am ET
Thinking about buying stock in Faraday Future Intelligent Electric, Processa Pharmaceuticals, ZW Data Action Technologies, Neuroone Medical Technologies, or Vistagen Therapeutics?
NEW YORK, Oct. 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FFIE, PCSA, CNET, NMTC, and VTGN.
Oct 13, 2023 01:08 pm ET
Processa Pharmaceuticals to Present at the ThinkEquity Conference
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from...
Sep 06, 2023 08:15 am ET
Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from...
Aug 17, 2023 08:05 am ET
Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from...
Aug 15, 2023 10:20 am ET
Sidoti Events, LLC’s Virtual August Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 16-17, 2023. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Aug 10, 2023 04:15 pm ET
Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering...
Aug 08, 2023 08:15 am ET
Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from...
Jun 14, 2023 04:15 pm ET
Next Generation Chemotherapy: Improved Treatment for More Patients
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering...
Jun 13, 2023 08:30 am ET
Longeveron Welcomes Three New Prominent Board Members
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today the election of three distinguished new...
May 22, 2023 08:05 am ET
Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering...
May 18, 2023 08:00 am ET
Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) today announces it has received guidance from the U.S. Food and Drug Administration (“FDA”) regarding the Company’s next trial for Next Generation Chemotherapy-Capecitabine...
Apr 28, 2023 08:15 am ET
Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering...
Mar 30, 2023 04:01 pm ET
Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a developer of Next Generation Chemotherapy drugs that provide a better safety-efficacy profile than their widely used FDA-approved counterparts, today provided an update...
Mar 23, 2023 08:30 am ET
Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a developer of Next Generation Chemotherapy drugs that provide a better safety-efficacy profile than their widely used FDA-approved counterparts, today announced that it...
Mar 17, 2023 08:30 am ET
Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a developer of Next Generation Chemotherapies (NGCs), today announced that the Company has dosed the first patient in its NGC-Capecitabine (combination of PCS6422 and...
Mar 07, 2023 08:30 am ET
Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), the developer of the Next Generation Chemotherapy drugs that will provide a better safety-efficacy profile than their widely used FDA-approved counterparts, today...
Feb 21, 2023 08:30 am ET
Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) reiterates the strategic prioritization of its pipeline of proprietary oncology drugs, defined as Next Generation Chemotherapies (NGCs). Previous studies with these NGCs...
Feb 15, 2023 08:30 am ET
Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a diversified clinical-stage company developing next generation chemotherapy drugs for patients who have unmet medical conditions and/or require better treatment options...
Feb 10, 2023 08:00 am ET
Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a diversified clinical-stage company developing next generation chemotherapy drugs for patients who have unmet medical conditions and/or require better treatment options...
Feb 03, 2023 07:34 am ET
Thinking about buying stock in Nordstrom, TMC the metals company, Gracell Biotechnologies, Processa Pharmaceuticals, or Mullen Automotive?
NEW YORK, Feb. 3, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JWN, TMC, GRCL, PCSA, and MULN.
Jan 04, 2023 08:30 am ET
Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), Dr. David Young, Processa Pharmaceuticals, CEO will present an update on Processa’s future therapeutic focus and strategy at the upcoming Biotech Showcase on January 11, 2023, at 10 am. This...
Dec 14, 2022 08:30 am ET
Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need condition, today announced positive top-line results...
Nov 08, 2022 04:00 pm ET
Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a diversified clinical-stage company developing drugs for patients who have unmet medical conditions and/or require better treatment options to improve a patient’s...
Nov 08, 2022 08:30 am ET
PCS12852 Improves Gastric Emptying in Gastroparesis Patients
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need condition, announces positive gastric emptying...
Nov 02, 2022 08:30 am ET
Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a...
Nov 01, 2022 08:30 am ET
Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need condition, announces positive results from its...
Sep 15, 2022 08:30 am ET
Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), (“Processa” or “Company”), a clinical stage biopharmaceutical company focused on developing products to improve survival and/or quality of life for patients who have an unmet medical need condition for...
Sep 07, 2022 08:30 am ET
Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition today announced that Dr. Dr. David...
Aug 16, 2022 08:30 am ET
Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company using its Regulatory Science process to more effectively develop products to improve the survival and/or quality of life for patients who have an unmet...
Aug 12, 2022 09:30 am ET
Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions and/or require better treatment options to improve a patient’s survival and/or...
Aug 05, 2022 03:00 pm ET
Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a...
Aug 04, 2022 09:30 am ET
Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions,...
Aug 03, 2022 04:00 pm ET
Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions,...
Jul 12, 2022 08:30 am ET
Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have unmet medical conditions announced today...
May 12, 2022 04:20 pm ET
Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or...
May 05, 2022 08:30 am ET
Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a...
Apr 20, 2022 08:30 am ET
Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions,...
Apr 05, 2022 08:30 am ET
Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis
Study will advance understanding of proper dosing while providing data to assist in the design of the next study for this >- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company...
Mar 30, 2022 04:00 pm ET
Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or...
Mar 23, 2022 08:30 am ET
Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a...
Mar 10, 2022 08:30 am ET
Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions,...
Jan 26, 2022 08:15 am ET
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or...
Nov 11, 2021 04:05 pm ET
Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or...
Nov 04, 2021 08:15 am ET
Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim Analysis
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions,...
Oct 26, 2021 08:30 am ET
Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced...
Oct 12, 2021 08:30 am ET
Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today...
Sep 16, 2021 11:05 am ET
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today...
Sep 16, 2021 08:30 am ET
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today...
Aug 23, 2021 04:00 pm ET
Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition today announced it will present at...
Aug 12, 2021 05:15 pm ET
Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have an unmet medical need condition, announces today financial results for...
Aug 06, 2021 08:30 am ET
Processa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Update on August 12 at 5:30 p.m. EST
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a...
Aug 04, 2021 08:30 am ET
Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition, announced today it has dosed the...
Aug 03, 2021 09:31 am ET
Thinking about buying stock in Autoweb, Processa Pharmaceuticals, Harmonic, Galmed Pharmaceuticals, or Sigma Labs?
NEW YORK, Aug. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AUTO, PCSA, HLIT, GLMD, and SGLB.
Jul 27, 2021 08:30 am ET
Processa Pharmaceuticals to Present at “Zooming with LD Micro” Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it will be presenting at the upcoming “Zooming with LD Micro” virtual investor event on Thursday, July 29th, 2021 at 12:00 PM ET. Investors and other individuals may access the...
Jul 08, 2021 11:20 am ET
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1x1 meetings with qualified investors throughout the event.
Jul 06, 2021 08:15 am ET
Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that the company will present at Access to Giving Virtual Conference. The presentation will be given by Processa’s Chief Executive Officer, Dr. David Young. Registration DetailsDate:...
Jun 23, 2021 09:35 am ET
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qualified investors throughout the three-day event.
Jun 17, 2021 09:15 am ET
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP) to license in RX-3117. RX-3117 is an oral, anticancer agent with an improved pharmacological...
Jun 08, 2021 09:15 am ET
Processa Set to Join Russell Microcap® Index
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, is set to join...
Jun 07, 2021 04:05 pm ET
Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today...
May 26, 2021 09:15 am ET
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today...
May 20, 2021 04:05 pm ET
Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lip
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced...
May 18, 2021 04:05 pm ET
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced...
May 13, 2021 04:55 pm ET
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or...
May 07, 2021 08:30 am ET
Processa Pharmaceuticals Schedules Conference Call to Discuss First Quarter Results and Provide Drug Development Update on May 13 at 5:30 p.m. EST
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announces...
Mar 25, 2021 04:06 pm ET
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or...
Mar 22, 2021 09:15 am ET
Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announces...
Mar 17, 2021 09:15 am ET
Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or...
Mar 02, 2021 09:15 am ET
Processa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is pleased to announce it has closed its previously announced private placement to institutional and accredited investors of $10.2 million. The Company sold 1,321,132 shares of the common stock at a...
Feb 22, 2021 08:30 am ET
Encode Ideas, L.P. Announces the Initiation of Research Coverage on Processa Pharmaceuticals, Inc.
Dover, Delaware--(Newsfile Corp. - February 22, 2021) - Encode Ideas, L.P. Initiates Research on Processa Pharmaceuticals, Inc. (NASDAQ: PCSA). The full research publication is available here and available on our website at www.encodelp.com.
Feb 17, 2021 08:00 am ET
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today...
Jan 11, 2021 10:50 am ET
Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today...
Nov 16, 2020 12:47 pm ET
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
via InvestorWire – Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical...
Nov 12, 2020 05:01 pm ET
Processa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update
via InvestorWire -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the...
Nov 05, 2020 09:15 am ET
Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need, is pleased...
Nov 03, 2020 09:20 am ET
Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on Nov. 12 at 5:30 p.m. ET
via InvestorWire -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical need...
Oct 13, 2020 09:30 am ET
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical needs, is pleased to...
Oct 06, 2020 04:05 pm ET
Processa Pharmaceuticals Closes $19.2 Million Public Offering
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of life of patients who have a...
Oct 02, 2020 06:00 am ET
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
Processa Pharmaceuticals, Inc. (OTCQB: PCSA; Nasdaq: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of life of...
Aug 27, 2020 09:30 am ET
PROCESSA PHARMACEUTICALS ENTERED INTO A CONTINGENT PRECEDENT IN-LICENSING AGREEMENT WITH ELION ONCOLOGY FOR THE DEVELOPMENT OF ENILURACIL (PCS6422) FOR THE TREATMENT OF ADVANCED GASTROINTESTINAL TUMOR
Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has entered into a contingent precedent exclusive licensing agreement with Elion Oncology, Inc. to develop, manufacture and commercialize eniluracil (PCS6422) globally. PCS6422 is...
Aug 20, 2020 09:30 am ET
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH YUHAN CORPORATION FOR THE DEVELOPMENT OF YH12852 IN FUNCTIONAL GASTROINTESTINAL DISORDERS
Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has entered into a licensing agreement with Yuhan Corporation, a South Korean based company, to license in YH12852. YH12852 is a small molecule drug in development for the...
Jun 01, 2020 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS ENTERED INTO AN AGREEMENT WITH APOSENSE, LTD TO LICENSE IN THE NEXT GENERATION IRINOTECAN DRUG
Processa Pharmaceuticals, Inc. (OTCQB: PCSA) announced today that it has signed an agreement with Aposense, LTD. to license in the patent rights and the know-how to develop and commercialize their next generation irinotecan cancer drug, ATT-11T....
Mar 30, 2020 04:00 pm ET
PROCESSA PHARMACEUTICALS TO MOVE FORWARD WITH A PCS499 PHASE 3 TRIAL AFTER A SUCCESSFUL FDA MEETING
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), announced the successful completion of their meeting with the U.S. Food and Drug Administration (FDA) for PCS499, its investigational product targeting the treatment of Necrobiosis Lipoidica (NL)....
Mar 17, 2020 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES RESULTS FROM THE PHASE 2 STUDY IN NECROBIOSIS LIPOIDICA
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced the completion of its...
Mar 05, 2020 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES FORMATION OF ITS MEDICAL AND SCIENTIFIC ADVISORY BOARD
Processa Pharmaceuticals, Inc. (OTCQB: PCSA) a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced today that they...
Feb 25, 2020 09:30 am ET
PROCESSA PHARMACEUTICALS PROVIDES SHAREHOLDER UPDATE
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have a high unmet medical need condition, provides a year-end review and an...
Feb 13, 2020 09:30 am ET
PROCESSA PHARMACEUTICALS APPOINTS GERALDINE PANNU AS AN INDEPENDENT DIRECTOR TO THE BOARD OF DIRECTORS
Processa Pharmaceuticals, Inc. (OTC: PCSA) a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need, announced today that Geraldine Pannu was...
Dec 20, 2019 04:10 pm ET
PROCESSA PHARMACEUTICALS ANNOUNCES 1 FOR 7 REVERSE STOCK SPLIT OF ITS COMMON STOCK
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced today that it will...
Dec 04, 2019 09:30 am ET
PROCESSA PHARMACEUTICALS PROVIDES AN UPDATE ON POSITIVE RESULTS FROM PCS-499 PHASE 2 TRIAL
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, provides an update on its...
Sep 03, 2019 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES THE LICENSING OF AN ANTI-FIBROTIC, ANTI-INFLAMMATORY DRUG FOR THE TREATMENT OF MULTIPLE UNMET MEDICAL NEED CONDITIONS
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced today that they have...
Aug 26, 2019 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES LAST PATIENT ENROLLED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today the last patient...
Jul 15, 2019 09:30 am ET
PROCESSA PHARMACEUTICALS PROVIDES A STUDY UPDATE FOR ITS ON-GOING PHASE 2 SAFETY AND TOLERABILITY CLINICAL TRIAL OF PCS-499
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, provides an update for its...
May 20, 2019 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES TODAY THAT THEY WILL BE PRESENTING AT THE JEFFRIES 2019 GLOBAL HEALTHCARE CONFERENCE ON FRIDAY, JUNE 7TH, 2019
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today that it will be...
Mar 11, 2019 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES TODAY THAT THEY WILL BE PRESENTING AT THE COWEN CONFERENCE ON WEDNESDAY - MARCH 13, 2019
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today that it will be...
Jan 29, 2019 09:30 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PCS-499 FOR THE TREATMENT OF NECROBIOSIS LIPOIDICA
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today the dosing of the...
Jan 09, 2019 09:00 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES PRESENTATION OF PCS499 DATA AT THE ANNUAL MEETING OF AMERICAN ACADEMY OF DERMATOLOGY
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition, announced today that the American...
Dec 06, 2018 09:00 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES UP-LISTING TO OTCQB MARKET
Processa Pharmaceuticals, Inc. (OTCQB: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today that its stock...
Oct 02, 2018 09:00 am ET
Processa Pharmaceuticals Receives FDA Clearance Of IND To Begin Phase 2 Clinical Development Of PCS-499 In Necrobiosis Lipoidica Patients
HANOVER, Md., Oct. 2, 2018 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (OTC: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted Processa clearance to proceed with a Phase 2 clinical trial of PCS-499 in patients with Necrobiosis Lipoidica (NL) under a recently submitted Investigational New Drug (IND) application.
Sep 10, 2018 09:00 am ET
Processa Pharmaceuticals Appoints James Stanker As Chief Financial Officer
HANOVER, Md., Sept. 10, 2018 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (OTC: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need, announced today that James Stanker was appointed Chief Financial Officer on September 5, 2018.
Jun 22, 2018 09:00 am ET
Processa Pharmaceuticals Receives Orphan Designation Status For PCS499 In Necrobiosis Lipoidica From The Food And Drug Administration (FDA)
HANOVER, Md., June 22, 2018 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (OTC: PCSA) a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have a high unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to its leading clinical compound PCS499 for treatment of Necrobiosis Lipoidica (NL).
Jun 01, 2018 12:00 pm ET
Processa Pharmaceuticals Raises $6.88 Million From Private Placements
HANOVER, Md., June 1, 2018 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (OTC: PCSA) is pleased to announce it has raised a total of $6.88 million from private placements.  The $6.88 million raise consists of 3 investments described below: $2.50 million from the first tranche of an on-going private placement; a private placement for funding of clinical trials of $1.80 million; and a mandatory conversion of 8% Senior Notes totaling $2.58 million.  For these 3 private placements, agent fees and estimated expenses payable by the Company are associated with the gross proceeds.
Mar 21, 2018 09:00 am ET
Processa Pharmaceuticals Announces That It Has Been Assigned The License For The Clinical Stage Compound CTP-499 And Plans To Develop The Drug In Multiple Unmet Medical Need Conditions
HANOVER, Md., March 21, 2018 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (OTC: PCSA) announced today that, as agreed in the asset purchase of Promet Therapeutics, LLC, Processa has been assigned the license for CTP-499 upon Promet's exercising of the exclusive option to license in CTP-499 from Concert Pharmaceuticals, Inc. 
Mar 21, 2018 09:00 am ET
PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS BEEN ASSIGNED THE LICENSE FOR THE CLINICAL STAGE COMPOUND CTP-499 AND PLANS TO DEVELOP THE DRUG IN MULTIPLE UNMET MEDICAL NEED CONDITIONS
HANOVER, MD, March 21, 2018 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTC: PCSA) announced today that, as agreed in the asset purchase of Promet Therapeutics, LLC, Processa has been assigned the license for CTP-499 upon Promet’s exercising of...
Mar 02, 2018 08:00 am ET
Processa Pharmaceuticals Announces Attendance at 2018 ROTH Conference
HANOVER, Md., March 2, 2018 /PRNewswire/ -- Processa Pharmaceuticals, Inc. ("Processa") (OTC PINK: PCSA), will attend and participate in meetings at the 30th annual ROTH Conference March 11-14, 2018 at the Ritz Carlton, Laguna Niguel in Orange County, CA.
Dec 11, 2017 08:03 am ET
Processa Pharmaceuticals Announces Reverse Stock Split and Launches New Website
HANOVER, Md., Dec. 11, 2017 /PRNewswire/ -- Processa Pharmaceuticals, Inc. (the "Processa") (OTC PINK: PCSA), formed from the merger of Promet Therapeutics and Heatwurx Inc., is an emerging clinical stage biotech company focused on the development of drugs for the treatment of high unmet medical need conditions.  Processa announced today that the Financial Industry Regulatory Association (FINRA) confirmed the below listed corporate actions requested by Processa:

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.